Strain-independent amplification of pathogens and vaccines thereto
This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.
1. A therapeutic autologous dendritic cell vaccine that elicits an immune response against specific pathogen antigens present in an HIV infected subject comprising a pharmaceutically acceptable carrier and a dendritic cell obtained or derived from said subject, wherein said dendritic cell comprises HIV polypeptides that:
a) correspond to multiple allelic variants of at least one polypeptide from multiple strains of HIV present in said subject;
b) include less than all of the polypeptides from any of said HIV strains; and
c) comprise truncated vpr polypeptides encoded by nucleic acids amplified from said subject using a vpr forward primer comprising the sequence set forth in SEQ ID NO:57 and/or 58 and a vpr reverse primer having the sequence set forth in SEQ ID NO:269, 270, 271, 272, and/or 273.
2. The therapeutic dendritic cell vaccine of claim 1 , wherein said nucleic acids are derived from nucleic acid amplification of HIV polynucleotides.
3. The therapeutic dendritic cell vaccine of claim 2 , wherein said nucleic acids are RNAs.
4. The therapeutic dendritic cell vaccine of claim 3 , wherein said RNAs are in vitro transcribed RNAs.
5. The therapeutic dendritic cell vaccine of claim 1 , wherein said dendritic cell further comprises one or more of the group of MY polypeptides selected from the group consisting of: gag polypeptides, rev polypeptides, env polypeptides, nef polypeptides, vpu polypeptides, vif polypeptides, and pol polypeptides.
6. The dendritic cell vaccine of claim 1 that helps to suppress the viral load level in said subject.
7. The therapeutic dendritic cell vaccine of claim 1 , wherein said truncated vpr polypeptide comprise vpr amino acid residues 1-69.
8. The therapeutic dendritic cell vaccine of claim 1 , wherein said nucleic acids amplified from said subject are variants of the portion of vpr set forth in nucleotides 5105-5311 of SEQ ID NO:388.
9. A method of treating a HIV-infected patient, comprising administering the vaccine of claim 1 to said patient.
10. A method of preparing an autologous therapeutic dendritic cell vaccine that elicits an immune response against specific pathogen antigens present in an HIV infected patient, comprising the step of transfecting antigen presenting cells obtained or derived from said patient with nucleic acids that:
a) encode multiple allelic variants of at least one HIV polypeptide from multiple strains of HIV present in said patient;
b) encode less than all of the HIV proteins from any of said HIV strains; and
c) comprise nucleic acids that encode truncated vpr polypeptides and were amplified using a vpr forward primer comprising the sequence set forth in SEQ ID NO:57 and/or 58 and a vpr reverse primer having the sequence set forth in SEQ ID NO:269, 270, 271, 272, and/or 273.
11. A therapeutic autologous dendritic cell vaccine that elicits an immune response against specific pathogen antigens present in an HIV infected subject, comprising a pharmaceutically acceptable carrier and a dendritic cell obtained or derived from said subject, wherein said dendritic cell comprises nucleic acids that:
a) encode multiple allelic variants of at least one polypeptide from multiple strains of HIV present in said subject;
b) encode less than all of the polypeptides from any of said HIV strains; and
c) comprise nucleic acids that encode truncated vpr polypeptides and were amplified using a vpr forward primer comprising the sequence set forth in SEQ ID NO:57 and/or 58 and a vpr reverse primer having the sequence set forth in SEQ ID NO:269, 270, 271, 272, and/or 273.
12. The therapeutic dendritic cell vaccine of claim 11 , wherein said nucleic acids that encode truncated vpr polypeptides are variants of the portion of vpr set forth in nucleotides 5105-5311 of SEQ ID NO:388.
13. The therapeutic dendritic cell vaccine of claim 11 , wherein said truncated vpr polypeptides comprise vpr amino acid residues 1-69.
14. The therapeutic dendritic cell vaccine of claim 11 , wherein said nucleic acids that encode truncated vpr polypeptides are derived from nucleic acid amplification of HIV polynucleotides.
15. The therapeutic dendritic cell vaccine of claim 14 , wherein said nucleic acids are RNAs.
16. The therapeutic dendritic cell vaccine of claim 15 , wherein said RNAs are in vitro transcribed RNAs.
17. The therapeutic dendritic cell vaccine of claim 11 , wherein said dendritic cell further comprises one or more of the group of HIV polypeptides selected from the group consisting of: gag polypeptides, rev polypeptides, env polypeptides, nef polypeptides, vpu polypeptides, vif polypeptides, and pol polypeptides.